Special Issue "Glioblastoma: State of the Art and Future Perspectives"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 December 2018)
Prof. Dr. Ghazaleh Tabatabai
Interdisciplinary Division of Neuro-Oncology, Hertie Institute for Clinical Brain Research, Center for CNS Tumors at CCC TS, University Hospital Tübingen, Eberhard Karls University Tübingen, Hoppe Seyler Strasse 3, 72076 Tübingen, Germany
Website | E-Mail
Interests: brain tumors; acquired resistance to therapy; tumor-associated microenvironment cell-based therapy; glioma mouse models
Glioblastoma is one of the most common types of primary cancer in the central nervous system. Median overall survival is in the range of 1.5 years even in selected clinical trials populations. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, resistance to therapy, migration and invasion, immunosuppression. With the entry of novel highthroughput technologies, significant progress has been made to understand molecular and immunological signatures underlying the pathology of glioblastoma. Clinical trial designs have shifted from investigating broad “one-for-all” treatment approaches to precision oncology designs.
Here, we aim at updating researchers and clinicians to provide a systemic view on glioblastoma by highlighting the progress made in basic, preclinical and clinical research and outlining future challenges. To this end, we welcome articles on basic, preclinical and clinical research in glioblastoma. In addition, we will present invited review articles on the topics of neurosurgical approaches, neuropathology and genetics, preclinical research and mouse models of glioblastoma, imaging, radiation therapy and tumor-treating fields, alkylating chemotherapy, immunotherapy, investigational therapies and precision oncology trials in glioblastoma.Prof. Dr. Ghazaleh Tabatabai
Dr. Hiroaki Wakimoto
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- neurosurgical approaches
- neuropathology and genetics
- preclinical research in glioblastoma
- mouse models of glioblastoma
- imaging, radiation therapy of glioblastoma
- tumor-treating fields
- alkylating chemotherapy
- investigational therapies
- precision oncology trials